# "Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"

> **NCT02375217** · PHASE4 · COMPLETED · sponsor: **American University of Beirut Medical Center** · enrollment: 56 (actual)

## Conditions studied

- Anesthesia Recovery

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Sugammadex
- **DRUG:** Neostigmine
- **DRUG:** glycopyrrolate

## Key facts

- **NCT ID:** NCT02375217
- **Lead sponsor:** American University of Beirut Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02375217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02375217, ""Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02375217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*